V. Ratziu, A. Sanyal, S. Harrison
Jan 13, 2020
Citations
4
Influential Citations
200
Citations
Quality indicators
Journal
Hepatology
Abstract
Cenicriviroc (CVC) is a C‐C chemokine receptors type 2 and 5 dual antagonist under evaluation for treating liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). Year 1 primary analysis of the 2‐year CENTAUR study showed that CVC had an antifibrotic effect without impacting steatohepatitis. Herein, we report the final data from year 2 exploratory analyses.